Dechra Pharmaceuticals Gestione

Gestione criteri di controllo 4/4

Dechra Pharmaceuticals Il CEO è Ian Page, nominato in Nov2001, e ha un mandato di 21.42 anni. la retribuzione annua totale è £ 2.07M, composta da 28.8% di stipendio e 71.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.36% delle azioni della società, per un valore di MX$ 338.86M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.8 anni e 4.2 anni.

Informazioni chiave

Ian Page

Amministratore delegato

UK£2.1m

Compenso totale

Percentuale dello stipendio del CEO	28.8%
Mandato del CEO	21.4yrs
Proprietà del CEO	0.4%
Durata media del management	5.8yrs
Durata media del Consiglio di amministrazione	4.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Ian Page rispetto agli utili di Dechra Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Dec 31 2022	n/a	n/a	UK£40m
Sep 30 2022	n/a	n/a	UK£49m
Jun 30 2022	UK£2m	UK£597k	UK£58m
Mar 31 2022	n/a	n/a	UK£66m
Dec 31 2021	n/a	n/a	UK£73m
Sep 30 2021	n/a	n/a	UK£64m
Jun 30 2021	UK£3m	UK£551k	UK£56m
Mar 31 2021	n/a	n/a	UK£50m
Dec 31 2020	n/a	n/a	UK£44m
Sep 30 2020	n/a	n/a	UK£39m
Jun 30 2020	UK£2m	UK£517k	UK£34m
Mar 31 2020	n/a	n/a	UK£31m
Dec 31 2019	n/a	n/a	UK£29m
Sep 30 2019	n/a	n/a	UK£30m
Jun 30 2019	UK£3m	UK£500k	UK£31m
Mar 31 2019	n/a	n/a	UK£28m
Dec 31 2018	n/a	n/a	UK£25m
Sep 30 2018	n/a	n/a	UK£30m
Jun 30 2018	UK£3m	UK£500k	UK£36m
Mar 31 2018	n/a	n/a	UK£40m
Dec 31 2017	n/a	n/a	UK£43m
Sep 30 2017	n/a	n/a	UK£35m
Jun 30 2017	UK£3m	UK£490k	UK£26m
Mar 31 2017	n/a	n/a	UK£19m
Dec 31 2016	n/a	n/a	UK£11m
Sep 30 2016	n/a	n/a	UK£12m
Jun 30 2016	UK£2m	UK£440k	UK£13m

Compensazione vs Mercato: La retribuzione totale di Ian ($USD 2.58M ) è circa la media per le aziende di dimensioni simili nel mercato MX ($USD 2.48M ).

Compensazione vs guadagni: La retribuzione di Ian è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Ian Page (61 yo)

21.4yrs

Mandato

UK£2,073,000

Compensazione

Mr. Ian D. Page has been the Chief Executive Officer and Managing Director of Dechra Pharmaceuticals Plc since November 2001 and 1998 respectively and also serves as its Executive Director since June 13, 1...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Ian Page	CEO, MD & Executive Director	21.4yrs	UK£2.07m	0.36% MX$ 338.9m
Paul Sandland	CFO & Executive Director	4yrs	UK£932.00k	0.010% MX$ 9.8m
Anthony Griffin	MD of Dechra Veterinary Products for Europe & Executive Director	10.9yrs	UK£856.00k	0.033% MX$ 31.0m
Patrick Meeus	Group Scientific Officer	less than a year	Nessun dato	Nessun dato
Katy Clough	Group HR Director	no data	Nessun dato	Nessun dato
Mike Eldred	President of North America	no data	Nessun dato	Nessun dato
Melanie Hall	Company Secretary	5.8yrs	Nessun dato	Nessun dato

5.8yrs

Durata media

55.5yo

Età media

Gestione esperta: Il team dirigenziale di DPH N è esperto e expertise (durata media dell'incarico 5.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Ian Page	CEO, MD & Executive Director	25.8yrs	UK£2.07m	0.36% MX$ 338.9m
Paul Sandland	CFO & Executive Director	3.5yrs	UK£932.00k	0.010% MX$ 9.8m
Anthony Griffin	MD of Dechra Veterinary Products for Europe & Executive Director	10.4yrs	UK£856.00k	0.033% MX$ 31.0m
Ishbel Jean Macpherson	Independent Non-Executive Director	10.2yrs	UK£83.00k	0.0059% MX$ 5.6m
Geeta Gopalan	Non-Executive Director	less than a year	Nessun dato	Nessun dato
Lawson MacArtney	Senior Independent Director	6.3yrs	UK£78.00k	0.0052% MX$ 4.9m
Alison Platt	Non-Executive Chairman	3.1yrs	UK£132.00k	0.0033% MX$ 3.1m
Lisa Morrison	Designated Non-Executive Director	4.2yrs	UK£72.00k	0.0012% MX$ 1.2m
John Shipsey	Non-Executive Director	less than a year	UK£5.00k	0.00053% MX$ 505.4k

4.2yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di DPH N sono considerati esperti (durata media dell'incarico 4.2 anni).

Dechra Pharmaceuticals Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Less than half of directors are independent

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

Less than half of directors are independent

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Less than half of directors are independent

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Announces Executive Changes

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Non-Executive Chairman recently bought Mex$2.6m worth of stock

Investor sentiment improved over the past week

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Investor sentiment deteriorated over the past week

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Less than half of directors are independent

Upcoming dividend of UK£0.29 per share

Less than half of directors are independent

Non-Executive Director recently bought Mex$178k worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Less than half of directors are independent

Board Member recently sold Mex$27m worth of stock

Non-Executive Director recently bought Mex$587k worth of stock

Non-Executive Director recently bought Mex$587k worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

CEO, MD & Executive Director recently sold Mex$279m worth of stock

Dechra Pharmaceuticals PLC Launches Mirataz

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

Non-Executive Director recently bought Mex$712k worth of stock

Independent Non Executive Director recently sold Mex$3.5m worth of stock

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media